Keyword Connections

•  Albert Beth
•  Alexander Zaika
•  BethAnn McLaughlin
•  Brian Wadzinski
•  Bruce Carter
•  Charles Sanders
•  Chris Wright
•  Claus Schneider
•  David Gailani
•  Dayanidhi Raman
•  Erin Gribben
•  Eugenia Gurevich
•  Hassane Mchaourab
•  Heidi Hamm

•  James Goldenring
•  Jean-Philippe Cartailler
•  Jingqiong Kang
•  Kathleen Gould
•  Kevin Currie
•  Kyle Brown
•  Manuel Ascano
•  Mark Vincent dela Cerna
•  Martin Gallagher
•  Nick Reiter
•  Qi Zhang
•  Richard Caprioli
•  Robert Beauchamp
•  Roger Colbran

•  Romell Gletten
•  Sean Davies
•  Stephen Brandt
•  Stephen Fesik
•  Stephen Hann
•  Sudan Loganathan
•  Susan Guttentag
•  Terunaga Nakagawa
•  Timothy Cover
•  Todd Graham
•  Trayambak Basak
•  Vsevolod Gurevich
•  Walter Chazin

Resources

• B6;129S6-Ptf1a{tdTomatoMgn}/Vu
• Cas9 protein and RNA oligonucleotides
• Conditional knockout mice produced with CRISPR-Cas9
• Western blotting

Communities

• Davies Lab
• Goldenring Lab
• The Vanderbilt Antibody and Protein Resource
• Wright Lab

Publications

• Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
  Berlin J
  (2013) N Engl J Med 369: 1059-60
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
  Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R
  (2012) N Engl J Med 366: 207-15
• Altered nuclear transfer in stem-cell research - a flawed proposal.
  Melton DA, Daley GQ, Jennings CG
  (2004) N Engl J Med 351: 2791-2
• Multiple biomarkers for the prediction of first major cardiovascular events and death.
  Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS
  (2006) N Engl J Med 355: 2631-9
• Reversible cardiomyopathy associated with sunitinib and sorafenib.
  Uraizee I, Cheng S, Moslehi J
  (2011) N Engl J Med 365: 1649-50
• Inhibition of mutated, activated BRAF in metastatic melanoma.
  Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB
  (2010) N Engl J Med 363: 809-19
• Anthracyclines and heart failure.
  Sawyer DB
  (2013) N Engl J Med 368: 1154-6
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A
  (2012) N Engl J Med 366: 707-14
• A novel channelopathy in pulmonary arterial hypertension.
  Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, Germain M, Trégouët DA, Borczuk A, Rosenzweig EB, Girerd B, Montani D, Humbert M, Loyd JE, Kass RS, Chung WK
  (2013) N Engl J Med 369: 351-361
• Efficacy and safety of recombinant human activated protein C for severe sepsis.
  Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
  (2001) N Engl J Med 344: 699-709
• Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
  Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA, Loyd JE
  (2001) N Engl J Med 345: 319-24
• Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.
  Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D
  (2000) N Engl J Med 342: 541-9
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
  Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA
  (2008) N Engl J Med 358: 1109-17
• Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.
  Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG
  (2010) N Engl J Med 363: 343-54
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
  Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial
  (2007) N Engl J Med 356: 2271-81
• Cancer-drug discovery and cardiovascular surveillance.
  Groarke JD, Cheng S, Moslehi J
  (2013) N Engl J Med 369: 1779-81
• Death, destruction, and the proteasome.
  Tansey WP
  (2004) N Engl J Med 351: 393-4
• Chemotherapy and immunotherapy in metastatic colorectal cancer.
  Pohlmann PR, Mernaugh RL, Goff LW
  (2009) N Engl J Med 360: 2134; author reply 2135-6
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
  Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group
  (2008) N Engl J Med 359: 2195-207
• Erlotinib in lung cancer.
  Pao W, Ladanyi M, Miller VA, Lung Cancer Oncogenome Group
  (2005) N Engl J Med 353: 1739-41; author reply 1739-41
• Rational use of analgesic and antiinflammatory drugs.
  Crofford LJ
  (2001) N Engl J Med 345: 1844-6
• Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
  Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS
  (2004) N Engl J Med 350: 655-63
• NFKBIA deletion in glioblastomas.
  Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR
  (2011) N Engl J Med 364: 627-37
• Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
  Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH
  (1988) N Engl J Med 318: 869-76